Posting of Annual Report and Notice of Meeting

Convatec Group PLC
15 April 2024
 

15 April 2024

Convatec Group Plc
("Convatec" or "the Company")

Annual Report and Accounts 2023 and Notice of Annual General Meeting

The Company announces that the following documents are available on its website at www.convatecgroup.com

-     Annual Report and Accounts 2023;

-     Notice of Annual General Meeting; and  

-     Form of Proxy.

In compliance with Listing Rule 9.6.1, copies of these documents have been submitted to the National Storage Mechanism and are available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Printed copies of these documents have also been sent to shareholders who have requested hard copies.

 

 

 

 

 

 

 

Enquiries 

 

Ria Banerjee, Group Deputy Company Secretary                                                                        +44(0)7425 655 845

 

Cosec@convatec.com  

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92 

 

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2022 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings